Cantargia receives Notice of Allowance from USPTO for expanded protection in treatment of leukemia
Cantargia AB (“Cantargia”) has been notified that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US patent application no. 15/242,242 which is the company’s second, follow-up patent application in the hematological cancer patent family. If granted, it adds further protection to Cantargias robust portfolio of patents covering treatment of solid tumors and hematological cancers using antibodies against IL1RAP.Cantargia already holds an approved parent patent in the USA covering a method of using IL1RAP as target molecule for antibody treatment of